Primary biliary cholangitis (PBC) is a slowly progressive chronic cholestatic liver disease that, in a subgroup of patients, may result in liver failure or death. The definition of specific risk profiles, i.e. risk stratification, is of critical importance for the identification of these subgroups and thereby the targeting of care. Over the last few years large multicentre cohort studies have improved our knowledge regarding factors associated with progressive disease. Stratification based on biochemical response to ursodoxycholic acid provides a readily available measure to identify groups that might benefit from additional therapies to further improve prognosis. In addition, serum total bilirubin and alkaline phosphatase are now considered the most robustly validated biomarkers of long-term outcome in PBC and are used as endpoints in clinical trials. The GLOBE score and UK-PBC risk score enable us to quantify the risk of future events for the individual patient, allowing more individualized risk prediction. In this review, we discuss both established prognostic factors and newly developed tools to estimate prognosis in PBC, highlighting their strengths, limitations and applicability in clinical practice.

, , ,,
Best Practice and Research in Clinical Gastroenterology
Department of Gastroenterology & Hepatology

Goet, J.C. (Jorn C.), Harms, M., Carbone, M. (Marco), & Hansen, B.E. (Bettina E.). (2018). Risk stratification and prognostic modelling in primary biliary cholangitis. Best Practice and Research in Clinical Gastroenterology. doi:10.1016/j.bpg.2018.06.006